INDICATIONS Nimodipine is indicated for the treatment of ischaemic neurological deficits following aneurysmal subarachnoid haemorrhage. DOSAGE Recommended dose - Aneurysmal Subarachnoid Haemorrhage For the first two hours of treatment 1 mg of nimodipine, i.e. 5 ml Nimotop solution, (about 15 ?????g/kg bw/h), should be infused each hour via a central catheter. If it is well tolerated, the dose should be increased after two hours to 2 mg nimodipine, i.e. 10 ml Nimotop solution per hour (about 30 ?????g/kg bw/h), providing no severe decrease in blood pressure is observed. Patients of body weight less than 70 kg or with unstable blood pressure should be started on a dose of 0.5 mg nimodipine per hour (2.5 ml of Nimotop solution), or less if necessary. Duration of treatment Aneurysmal subarachnoid haemorrhage Intravenous treatment should begin as early as possible after neurological deficit occurs due to arterial spasm, post subarachnoid haemorrhage. This should continue for at least five days up to a maximum of 14 days. In the event of surgical intervention during treatment, administration of nimodipine should be continued (dose as above) for at least five days. Nimotop solution may be used with or without pre-treatment with Nimotop tablets. In the event of Nimotop tablets and Nimotop solution being administered sequentially the total duration of treatment should not exceed 21 days. Nimotop solution should not be administered for longer than 14 days. Nimotop solution and tablets should not be used concomitantly   Paediatric Population The safety and efficacy of Nimotop in patients under 18 years of age have not been established. Method of administration Nimotop solution is administered as a continuous I.V. infusion via a central catheter using an infusion pump. It should be connected to a three-way stopcock using the infusion line provided. Nimotop solution must NOT be added to an infusion bag or bottle and must NOT be mixed with other drugs. Nimotop solution may be used during anaesthesia, angiography or surgical procedures. PREGNANCY AND LACTATION Nursing mothers should not breast-feed when taking this drug. SIDE EFFECTS Headache, Nausea,, Allergic reaction, Rash ACTIVE INGREDIENT Nimodipine